Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138380 | 0.85 | PTPN11 (0.31) | NR1I2SMARCA2SMARCA4PBRM1PTPN11 | |
| SCHEMBL21138133 | 0.84 | ALDH1A1 (0.42) | NR1I2SMARCA2SMARCA4PBRM1ADORA3 | |
| SCHEMBL21138230 | 0.84 | ALDH1A1 (0.42) | NR1I2SMARCA2SMARCA4PBRM1ADORA3 | |
| SCHEMBL21057262 | 0.84 | ALDH1A1 (0.42) | NR1I2SMARCA2SMARCA4PBRM1ADORA3 | |
| SCHEMBL21159348 | 0.82 | MEN1 (0.41) | NR1I2SMARCA2SMARCA4PBRM1ADORA3 | |
| SCHEMBL19917131 | 0.81 | NR1I2 (0.37) | NR1I2SMARCA2SMARCA4PBRM1ADORA3 | |
| SCHEMBL21057507 | 0.79 | TLR7 (0.36) | ADORA3TLR7AHCYTNK2PTPN11 | |
| SCHEMBL21138232 | 0.78 | ADORA3 (0.36) | ADORA3AHCYTNK2PTPN11NUDT1 | |
| SCHEMBL21057266 | 0.78 | ADORA3 (0.38) | PBRM1ADORA3TLR7AHCYPTPN11 | |
| SCHEMBL21138748 | 0.76 | NUDT1 (0.39) | ADORA3TNK2PTPN11NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | NR1I2 2630/4885SMARCA2 3684/4885SMARCA4 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.